ArticleFrontiers in oncology2025
Spleen EBV-positive inflammatory follicular dendritic cell sarcoma: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current concepts of Helicobacter pylori infection.European journal of medical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma (EBV+ IFDCS) is a rare tumor that typically arises in the liver or spleen and is characterized by spindle-shaped cells within a dense lymphoplasmacytic background. We report a case of a 64-year-old woman with an incidental splenic mass found during routine imaging. MRI showed a 4.8 cm lesion with progressive enhancement. The patient underwent laparoscopic partial splenectomy. Histopathological examination revealed features consistent with EBV+ IFDCS, including positivity for CD21, CD23, CD35, SMA, EMA, and EBER. EBV+ IFDCS often presents with nonspecific symptoms and imaging findings, making diagnosis challenging. Definitive diagnosis relies on histology, immunohistochemistry, and confirmation of EBV infection. Most cases follow an indolent clinical course and have a favorable prognosis after complete surgical resection, though rare aggressive cases have been reported. Understanding its clinicopathological and molecular features is essential for accurate diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.